Phathom Pharmaceuticals (PHAT) Scheduled to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.57) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its earnings results on Thursday, August 8th. The company reported ($1.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.04. The business had revenue of $7.32 million for the quarter, compared to analyst estimates of $5.65 million. On average, analysts expect Phathom Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Phathom Pharmaceuticals Trading Down 3.0 %

Shares of PHAT stock opened at $18.37 on Wednesday. The stock has a 50 day simple moving average of $17.20 and a 200-day simple moving average of $13.17. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -3.58 and a beta of 0.72. Phathom Pharmaceuticals has a 12-month low of $6.07 and a 12-month high of $19.71.

Wall Street Analyst Weigh In

Several research firms have issued reports on PHAT. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th. The Goldman Sachs Group increased their price target on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, September 13th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.